NASDAQ:PROK ProKidney (PROK) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free PROK Stock Alerts $2.12 -0.59 (-21.77%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.06▼$3.0250-Day Range$1.36▼$2.8452-Week Range$1.12▼$13.51Volume1.53 million shsAverage Volume1.07 million shsMarket Capitalization$486.20 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get ProKidney alerts: Email Address ProKidney MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside348.1% Upside$9.50 Price TargetShort InterestBearish26.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 9 Articles This WeekInsider TradingSelling Shares$232,392 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.65) to ($0.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.08 out of 5 starsMedical Sector576th out of 915 stocksBiological Products, Except Diagnostic Industry95th out of 153 stocks 3.2 Analyst's Opinion Consensus RatingProKidney has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageProKidney has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted26.69% of the float of ProKidney has been sold short.Short Interest Ratio / Days to CoverProKidney has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.Change versus previous monthShort interest in ProKidney has recently decreased by 17.31%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldProKidney does not currently pay a dividend.Dividend GrowthProKidney does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PROK. Previous Next 3.0 News and Social Media Coverage News SentimentProKidney has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for ProKidney this week, compared to 1 article on an average week.Search Interest9 people have searched for PROK on MarketBeat in the last 30 days. MarketBeat Follows6 people have added ProKidney to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProKidney insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $232,392.00 in company stock.Percentage Held by Insiders44.99% of the stock of ProKidney is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions51.59% of the stock of ProKidney is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ProKidney are expected to decrease in the coming year, from ($0.65) to ($0.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProKidney is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProKidney is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About ProKidney Stock (NASDAQ:PROK)ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Read More PROK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PROK Stock News HeadlinesApril 24, 2024 | insidertrades.comInsider Selling: ProKidney Corp. (NASDAQ:PROK) SVP Sells 16,438 Shares of StockApril 19, 2024 | insidertrades.comDarin J. Weber Sells 17,238 Shares of ProKidney Corp. (NASDAQ:PROK) StockApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.April 26, 2024 | finance.yahoo.comDiabetic Kidney Disease (DKD) - Market Insight, Epidemiology and Market Forecast - 2032April 24, 2024 | americanbankingnews.comProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber Sells 16,438 SharesApril 21, 2024 | americanbankingnews.comProKidney (NASDAQ:PROK) Stock Price Down 2.5%April 20, 2024 | finance.yahoo.comPROK Apr 2024 5.000 putApril 19, 2024 | americanbankingnews.comDarin J. Weber Sells 84,103 Shares of ProKidney Corp. (NASDAQ:PROK) StockApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.April 19, 2024 | americanbankingnews.comProKidney (NASDAQ:PROK) Shares Gap Down After Insider SellingMarch 26, 2024 | bizjournals.comDuring manufacturing pause, ProKidney increases R&D spending to $106.7MMarch 25, 2024 | globenewswire.comProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical OperationsMarch 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProKidney Amidst Strategic Clinical Advancements and Solid Financial OutlookMarch 21, 2024 | globenewswire.comProKidney Reports Full Year 2023 Financial Results and Recent Corporate HighlightsMarch 7, 2024 | realmoney.thestreet.comProKidney assumed with an Equal Weight at Morgan StanleyFebruary 29, 2024 | globenewswire.comProKidney to Participate in Jefferies Biotech on the Bay SummitFebruary 17, 2024 | finance.yahoo.comPROK Mar 2024 7.500 callFebruary 16, 2024 | bizjournals.comNorth Carolina biotech tops $400M in funding for asthma treatmentFebruary 9, 2024 | fool.comProKidney (NASDAQ: PROK)January 3, 2024 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on ProKidney (PROK)December 28, 2023 | bizjournals.comStories to Watch in 2024: Leadership changes, manufacturing pause make 2024 critical year for ProKidneyDecember 16, 2023 | ca.finance.yahoo.comPROK Jan 2024 10.000 callDecember 13, 2023 | finance.yahoo.comHere's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock NowNovember 30, 2023 | bizjournals.comProKidney makes two changes to C-suite, terminating long-serving COO and promoting from within for chief business officerNovember 30, 2023 | finance.yahoo.comProKidney Appoints Nikhil Pereira-Kamath, MBA, as Chief Business OfficerNovember 21, 2023 | msn.comProKidney former 10% owner Chamath Palihapitiya discloses sale of over 7M sharesNovember 21, 2023 | finance.yahoo.comProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx ConferenceSee More Headlines Receive PROK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProKidney and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PROK CUSIPN/A CIK1850270 Webwww.prokidney.com Phone336-999-7028FaxN/AEmployees163Year FoundedN/APrice Target and Rating Average Stock Price Target$9.50 High Stock Price Target$16.00 Low Stock Price Target$3.00 Potential Upside/Downside+348.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,470,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-7.66% Debt Debt-to-Equity RatioN/A Current Ratio14.94 Quick Ratio14.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($4.84) per share Price / Book-0.44Miscellaneous Outstanding Shares229,340,000Free Float126,162,000Market Cap$486.20 million OptionableOptionable Beta1.08 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Timothy A. Bertram D.V.M. (Age 69)Ph.D., Founder Comp: $970.4kMr. Todd C. Girolamo Esq. (Age 59)J.D., M.B.A., Chief Legal Officer & Secretary Comp: $600.17kDr. Bruce Culleton M.D.CEO & DirectorMr. James Coulston CPA (Age 47)Chief Financial Officer Dr. Glenn Schulman M.P.H.Pharm. D., Pharm.D., Senior Vice President of Investor RelationsMs. Mary Weger (Age 65)Chief People Officer Dr. Joseph M. Stavas M.D.M.P.H., Senior VP of Interventional Procedures & Patient SafetyDr. Darin J. Weber Ph.D. (Age 56)Chief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access Mr. Nikhil L. Pereira-KamathChief Business OfficerMr. Richard WilliamsSenior Vice President of Information TechnologyMore ExecutivesKey CompetitorsPrime MedicineNYSE:PRMENovavaxNASDAQ:NVAXAllogene TherapeuticsNASDAQ:ALLOValnevaNASDAQ:VALNExscientiaNASDAQ:EXAIView All CompetitorsInsiders & InstitutionsZullo Investment Group Inc.Bought 19,420 shares on 4/24/2024Ownership: 0.008%Darin J WeberSold 16,438 sharesTotal: $41,259.38 ($2.51/share)Darin J WeberSold 800 sharesTotal: $2,032.00 ($2.54/share)Darin J WeberSold 17,238 sharesTotal: $43,095.00 ($2.50/share)Darin J WeberSold 84,103 sharesTotal: $145,498.19 ($1.73/share)View All Insider TransactionsView All Institutional Transactions PROK Stock Analysis - Frequently Asked Questions Should I buy or sell ProKidney stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProKidney in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PROK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PROK, but not buy additional shares or sell existing shares. View PROK analyst ratings or view top-rated stocks. What is ProKidney's stock price target for 2024? 3 Wall Street analysts have issued twelve-month price objectives for ProKidney's stock. Their PROK share price targets range from $3.00 to $16.00. On average, they predict the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 348.1% from the stock's current price. View analysts price targets for PROK or view top-rated stocks among Wall Street analysts. How have PROK shares performed in 2024? ProKidney's stock was trading at $1.78 at the beginning of the year. Since then, PROK shares have increased by 19.1% and is now trading at $2.12. View the best growth stocks for 2024 here. Are investors shorting ProKidney? ProKidney saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 11,560,000 shares, a decrease of 17.3% from the March 31st total of 13,980,000 shares. Based on an average daily volume of 702,200 shares, the days-to-cover ratio is presently 16.5 days. Approximately 26.7% of the shares of the stock are sold short. View ProKidney's Short Interest. When is ProKidney's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our PROK earnings forecast. How were ProKidney's earnings last quarter? ProKidney Corp. (NASDAQ:PROK) released its quarterly earnings data on Thursday, March, 21st. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. Who are ProKidney's major shareholders? ProKidney's stock is owned by a variety of retail and institutional investors. Top institutional investors include Zullo Investment Group Inc. (0.01%). Insiders that own company stock include Chamath Palihapitiya and Darin J Weber. View institutional ownership trends. How do I buy shares of ProKidney? Shares of PROK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PROK) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
